Skip to content

Qui Tam Suit Against J&J Sub Ortho Biotech Goes Forward

August 19, 2009

In a 47-page opinion, the 1st Circuit reinstated whistleblower claims against Johnson & Johnson subsidiary Ortho Biotech Products regarding alleged kickbacks and fraudulent marketing of the anemia drug Procrit.  The alleged fraud is estimated at $3-10 billion and potentially involves the largest damage claims in the history of the False Claims Act. The 1st Circuit’s decision adopts a “more flexible [pleading] standard” following a trend away from the strict pleading requirements some defendants have used to insinulate against false claims liability. According to the holding, a False Claims Act Complaint meets the pleading requirements of Rule 9(b) of the Federal Rules of Civil Procedure “by alleging particular details of a scheme to submit false claims paired with reliable indicia that lead to a strong inference that claims were actually submitted.”

The 1st Circuit Ortho Biotech Products Opinion

To report healthcare fraud, contact Frohsin & Barger.

Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s

%d bloggers like this: